Related Experiment Video

Updated: Jul 6, 2026

On-Chip Endothelial Inflammatory Phenotyping
12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin

Minodora Dobreanu1, D Dobreanu, Andrea Fodor

  • 1Department of Clinical Biochemistry-Immunology, University of Medicine and Pharmacy, Târgu Mureş, Romania. dobreanu@orizont.net

Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne
|March 13, 2008
PubMed

Insights

Atorvastatin significantly reduced monocyte and lymphocyte activation markers in patients with unstable angina. These anti-inflammatory effects of statins may improve cardiovascular outcomes beyond cholesterol reduction.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Inflammatory processes in coronary plaques are key to acute atherothrombotic events.
  • Statins, potent lipid-lowering drugs, possess anti-inflammatory and immunomodulatory properties independent of cholesterol reduction.

Purpose of the Study:

  • To investigate the impact of atorvastatin on monocyte and lymphocyte activation in patients with unstable angina (UA) and mild primary hypercholesterolemia.
  • To assess if atorvastatin's effects are linked to its cholesterol-lowering capabilities.

Main Methods:

  • A study involving 22 patients (12 UA, 10 stable coronary heart disease) after a 4-week drug-free baseline.
  • Treatment with atorvastatin 20 mg/day for 8 weeks.
  • Flow cytometry was used to measure monocyte and lymphocyte activation markers (CD14, HLA-DR, CD11b, 11c, 49d) pre- and post-treatment.

Main Results:

  • Patients with UA exhibited higher baseline expression of monocyte CD11b, 11c, CD14, and T lymphocyte CD11b compared to stable patients (p < 0.001).
  • Atorvastatin treatment led to a significant decrease in these activation markers in UA patients.
  • Reductions in adhesion molecules, C-reactive protein (CRP), and soluble intercellular adhesion molecule-1 (sICAM-1) were observed.

Conclusions:

  • Atorvastatin effectively reduces monocyte and lymphocyte activation in patients with unstable angina.
  • These immunomodulatory effects may contribute to the clinical benefits of atorvastatin in coronary artery disease, irrespective of lipid-lowering.
  • Further research into these non-lipid-lowering mechanisms is warranted.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Inflammation01:38

Inflammation

Overview
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...